Is Outlook Therapeutics, Inc. (OTLK) Stock Halal or Haram?
Outlook Therapeutics, Inc. (OTLK) - Halal (Shariah-Compliant)
Outlook Therapeutics, Inc. (OTLK) is classified as Halal (Shariah-Compliant) according to AAOIFI Shariah screening standards. This assessment is based on business activity screening and financial ratio analysis using the AAOIFI methodology.
Business Activity Screen
Sector
Healthcare
Industry
Biotechnology
Result
Pass
Reason
The sector "Healthcare" and industry "Biotechnology" are not in the excluded categories.
Financial Ratios
Debt Ratio
Value: 15.4% | Threshold: 30% | Result: Pass
Cash & Interest-bearing Securities Ratio
Value: 9.4% | Threshold: 30% | Result: Pass
Non-Permissible Income Ratio
Value: 1.9% | Threshold: 5% | Result: Pass
Dividend Purification
Purification percentage: 1.91%.Based on the company's financial statements, approximately 1.91% of dividend income should be donated to charity for purification. This is derived from identified interest income (1.91% of total income). Some scholars may differ on the exact calculation method.
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Frequently Asked Questions
Is Outlook Therapeutics, Inc. (OTLK) stock halal to invest in?
According to AAOIFI Shariah screening standards, Outlook Therapeutics, Inc. (OTLK) is currently classified as Halal (Shariah-Compliant). This is based on both business activity and financial ratio screening.
Does Outlook Therapeutics, Inc. have any interest income?
Based on the company's financial statements, approximately 1.91% of dividend income should be donated to charity for purification. This is derived from identified interest income (1.91% of total income). Some scholars may differ on the exact calculation method.
Uses quarterly data
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
United StatesNASDAQHealthcare
Screened using AAOIFI Standard No. 21 on October 20, 2026. Financial ratios compared against market capitalization. Different methodologies may produce different results. Learn how we screen.
Screened using AAOIFI Shariah Standard No. 21 (3 ratios). Debt and interest-bearing deposits must each be under 30% of market capitalization, and non-permissible income under 5% of total income. This screening is for educational purposes only and does not constitute a fatwa or religious ruling. Results are based on publicly available financial data and automated analysis. Users should consult qualified Islamic scholars and financial advisors for personal investment decisions. Financial data may be delayed or incomplete. Past compliance does not guarantee future status.
Verdict history
Free with an account.
No verdict changes recorded since first screened on Jul 14, 2026. We started recording changes on Oct 19, 2026.
Dates are when Mizaan recorded the change. Tracked and watched stocks are re-checked weekly; other stocks are re-screened on demand.
Get More on the Mizaan App
Live charts, market cap, financials, AI business analysis, portfolio tracking, and compliance alerts — all on your phone.
Frequently Asked Questions
According to AAOIFI Shariah screening standards, Outlook Therapeutics, Inc. (OTLK) is currently classified as Halal (Shariah-Compliant). This is based on both business activity and financial ratio screening.
Outlook Therapeutics, Inc.'s interest income ratio is 9.4% of total revenue. AAOIFI standards require this to be below 30%.
OTLK is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.
Outlook Therapeutics, Inc.'s compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.
You can save OTLK to your Mizaan portfolio to track its compliance status over time. Mizaan will update the screening whenever new financial data is available, so you always have the latest result.
Dividends from Outlook Therapeutics, Inc. require purification. Approximately 1.91% of dividend income should be donated to charity to cleanse earnings from non-permissible sources such as interest income.
Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.
Outlook Therapeutics, Inc.'s interest income ratio is 9.4% of total revenue. AAOIFI standards require this to be below 30%.
What guidelines are used to determine if OTLK stock is Shariah-compliant?
OTLK is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.
How often is Outlook Therapeutics, Inc. stock reviewed for Shariah compliance?
Outlook Therapeutics, Inc.'s compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.
How can I stay updated on Outlook Therapeutics, Inc.'s compliance status?
You can save OTLK to your Mizaan portfolio to track its compliance status over time. Mizaan will update the screening whenever new financial data is available, so you always have the latest result.
Are dividends from Outlook Therapeutics, Inc. stock considered halal?
Dividends from Outlook Therapeutics, Inc. require purification. Approximately 1.91% of dividend income should be donated to charity to cleanse earnings from non-permissible sources such as interest income.
Do I need to pay Zakat on my Outlook Therapeutics, Inc. shares?
Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.
